<DOC>
	<DOCNO>NCT00255541</DOCNO>
	<brief_summary>This 52-week randomized , double-blind , parallel-group , multi-center , active-controlled ( glibenclamide ) study tesaglitazar patient type 2 diabetes , adequately control diet lifestyle advice alone run-in period . The study comprise 6 week placebo single blind run period follow 52-week double blind treatment period 3-week follow-up period . Tesaglitazar glibenclamide titrate optimal effect high tolerable dose first 12 week .</brief_summary>
	<brief_title>GALLANT 4 Tesaglitazar vs. Glibenclamide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Provision write informed consent Men woman &gt; =18 year age Female patient : postmenopausal , hysterectomized , childbearing potential , use reliable method birth control Diagnosed type 2 diabetes Treated diet alone treatment single oral antidiabetic agent low dos two oral antidiabetic agent Type 1 diabetes New York Heart Association heart failure Class III IV Treatment chronic insulin History hypersensitivity intolerance peroxisome proliferatoractivated receptor agonist ( like Actos Avandia ) , fenofibrate , metformin 3hydroxy3methylglutaryl coenzyme A reductase inhibitor ( statin ) History druginduced myopathy druginduced creatine kinase elevation , liver enzyme elevation , neutropenia ( low white blood cell ) Creatinine level twice normal range Creatine kinase 3 time upper limit normal Received investigational product clinical study within 12 week Any clinically significant abnormality identify physical examination , laboratory test electrocardiogram , judgment investigator would compromise patient 's safety successful participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>